Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)
A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Perifosine is looking good. Pipeline shows potential.
Recs
Fool biotech board likes this.
Recs
There are currently 4000 AEZS shares in my "fund" with break-even of around -0.22 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
I am convienced AEZS is on the right track but only time will tell. I am betting on AEZS to succeed. After all the shares are cheap and owning some shares may be a good thing in the long run.
Recs
Promising results. Bullish consensus.
Recs
Pipeline gamble
Recs
A few products comming out with important results by the end of the year
Recs
Deep pipeline and high hopes for perifosene.
Recs
Test for perifosine is coming out next year big market
Recs
I am in on Aeterna Zentaris with the Caps crowd, and my money.
Recs
Following Ultralong here. The chart looked up up to the recent selloff and think aezs should outperform the market as it regains it's feet
Recs
Cancer drug in Phase III looks promising as a treatment for multiple cancers. That plus the market pullback make this a good time to buy this promising micro-cap.
Recs
It's a biotech - it will either earn or burn. Based on the research I've done on Aeterna Zentaris and its partnership with Keryx, all signs are pointing that their phase 3 trial will bring a favorable result from the FDA. Aeterna Zentaris has 11 molecules in its pipeline of which 6 are currently in clinical trials. There's plenty of cash here as well, so minimal dilution to shareholders. Fell off a cliff with the rest of the market and down more than 40% in a month. Time to jump aboard on a hopeful dip tomorrow morning.
TMFUltraLong
Recs
Company hits on all cylinders as far as biotechs go, always positive news, keep investors in the loop. Very promising results so far, with a ton of licensing agreements to back them up. Incredibly battered down due to the overall financial uncertainty... this will hit $3 by the end of Q3 and $4 by FYE.
Recs
Cancer drug in the pipeline that has been shown to be successful and is now in Stage III testing. If successful, the stock price should soar. Also look to KERX who has agreements with Aeterna Zentraris to market the drug in US MExico and Canada.
the company also has several other drugs in the pipeline and a drug currently released. Even if the drug is not successful, the company has enough to last at least 2 years at the current burn rate.
Recs
Superb pipeline of drugs in various stages of development and trials.
Recs
Buying on pullback
Recs
cheap healthcare!
Recs
UltraLong
Recs
Gotta love their pipeline.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 59 : 1 2 3 Next »